A Phase 4 clinical trial involving semaglutide has reached completed status as of September 4, 2026. The study, registered as NCT06851962 and titled "Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes," examined pharmacogenetic-guided treatment approaches in the context of type 2 diabetes management.
According to the trial record, the study status is listed as completed, and the trial was conducted under a Phase 4 designation. Phase 4 studies typically occur after a drug has received regulatory approval, often gathering additional data in real-world or broader patient contexts.
The trial record identifies the study title and its completed status but does not include specific outcome data, efficacy findings, or safety results in the information provided. No results summary, numerical endpoints, or conclusions have been disclosed alongside this status update.
Semaglutide currently holds approved regulatory status. This update reflects only the change in the trial's recorded status to completed and does not represent a statement about the compound's effectiveness or safety profile beyond what has been reported in the trial registry.
Readers interested in learning more about semaglutide can consult the compound overview for additional background and context.